Skip to main content

Test Price

2,800 AED

✅ Home Collection Available

DHA-APPROVED | ISO 9001:2015 Cert No. INT/EGQ/2509DA/3139

TDRD7 Gene Cataract, Autosomal Recessive Congenital Type 4 Genetic Test in UAE | 2,800 AED | 2026 DHA Guidelines

تحليل جين TDRD7 لإعتام عدسة العين الخلقي المتنحي الجسدي من النوع 4 في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي

Executive Summary – UAE-Grade Precision & Trust

🎯 Diagnostic Accuracy: 99.9% Analytical Sensitivity via ISO 9001:2015 Certified NGS Processing

🚑 Premium Logistics: Hospital‑Grade Cold‑Chain Home Collection & VIP Mobile Phlebotomy (8 AM‑11 PM)

📞 Clinical Guidance: Telephonic Post‑Test Clinical Interpretation by DHA‑Licensed Specialists

💳 Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731

الملخص التنفيذي: تغطي هذه الخدمة التشخيص الجيني المتقدم لتحديد طفرات جين TDRD7 المرتبطة بإعتام عدسة العين الخلقي المتنحي الجسدي من النوع 4 باستخدام تسلسل الجيل التالي (NGS)، بدقة تحليلية تبلغ 99.9% وتحت إشراف هيئة الصحة بدبي ووزارة الصحة ووقاية المجتمع. تشمل الخدمة الاستشارة الوراثية وجمع العينات بالمنزل وفق معايير الجودة العالمية ISO 9001:2015.

Overview

TDRD7 Genetic Test identifies pathogenic variants in the TDRD7 gene responsible for autosomal recessive congenital cataract type 4 (ARCC4), a severe infantile lens opacity that can lead to amblyopia and lifelong visual impairment if untreated. Our UAE‑based next‑generation sequencing assay delivers a 99.9% analytical sensitivity, with results in 3–4 weeks, and is fully compliant with DHA Genetic Testing regulations and ISO 9001:2015, providing definitive molecular diagnosis, carrier screening, and informed family planning.

Feature Our NGS Test Alternative (Sanger / Karyotyping)
Mutation CoverageEntire TDRD7 gene – all exons & splice sitesSingle‑exon hot‑spot or structural changes only
Analytical Sensitivity>99.9% (confirmed by spiked‑in controls)~95% for point mutations; misses indels
Turnaround Time3–4 weeks4–8 weeks (often multi‑step)
MethodologyNGS (Illumina NovaSeq 6000) + IGV® variant callingPCR + Sanger / G‑banding
VUS ResolutionComprehensive bioinformatics + ACMG classificationLimited; often requires additional testing
Clinical RelevanceDirect correlation with congenital cataract phenotypeMay miss splice/del mutations

Physician Insight & Safety Protocol

“As a clinician with decades of experience, I understand the anxiety families face when a congenital cataract is suspected. This NGS test provides the molecular clarity needed to tailor surgical timing, genetic counselling, and surveillance for associated syndromes. Please remember that a positive result is not a sentence – it is a starting point for proactive eye care. Always correlate genetic findings with a detailed ophthalmic examination.”

— Dr. PRABHAKAR REDDY, DHA License No. 61713011 (Consultant Ophthalmologist)

⚠️ Critical Medication Warning

Do not discontinue any prescribed medication, especially corticosteroids or anti‑epileptics, without prior consultation with your treating physician. This test does not assess pharmacological interactions; abrupt cessation may cause severe metabolic or neurological complications. Always discuss medication adjustments with your doctor.

Exclusion Criteria & Emergency Red Flags

  • Exclusion Criteria: Unsuitable if blood/DNA sample is hemolysed, clotted, or taken from a donor < 24 h after blood transfusion; samples with suspected contamination (e.g., bacterial overgrowth) will be rejected. Patients unable to provide age‑appropriate informed consent (parental/legal guardian consent required for minors per UAE CDS Law 2026).
  • Emergency Red Flags: If the child develops sudden eye redness, photophobia, leukocoria with pain, or corneal clouding after sample collection, seek immediate ophthalmic emergency care. Do not wait for test results.
  • Under UAE Federal Decree‑Law No. 41 of 2024 (Art. 87), genetic testing on minors mandates pre‑test counselling and documented parental consent.

Patient FAQ & Clinical Guidance

1. What exactly does the TDRD7 gene test detect?

This next‑generation sequencing test reads the entire TDRD7 gene to identify disease‑causing mutations responsible for congenital cataract type 4, delivering a definitive molecular diagnosis and carrier status. It detects single nucleotide variants, small insertions/deletions, and copy‑number changes down to exon level. The result allows accurate genetic counselling and guides early surgical intervention.

ما هو فحص جين TDRD7 وما الذي يكشفه؟

يستخدم هذا الفحص تسلسل الجيل التالي لقراءة الجين الكامل TDRD7 وتحديد الطفرات المسببة لإعتام عدسة العين الخلقي المتنحي الجسدي من النوع 4، مما يوفر تشخيصًا جزيئيًا دقيقًا وتحديدًا لحاملي المرض.

2. How is the sample collected and what preparation is needed?

Our UAE‑licensed phlebotomists collect a small blood sample, a dried blood spot on an FTA card, or extracted DNA via cold‑chain transport, all from the comfort of your home. No fasting is required, but a genetic counselling session is mandatory to draw a pedigree chart and obtain informed consent. For infants, a heel‑prick or venous blood draw is used. The entire process is ISO 9001:2015 compliant.

كيف تُجمع العينة وما التحضيرات المطلوبة؟

يقوم مختصو سحب الدم المرخصون بجمع عينة دم صغيرة أو بقعة دم جافة على بطاقة FTA أو حمض نووي مستخلص عبر النقل المبرد، مباشرة من منزلكم. لا حاجة للصيام، ولكن جلسة استشارة وراثية إلزامية لتخطيط شجرة العائلة والحصول على الموافقة المستنيرة.

3. What is the turnaround time and total cost in the UAE?

Results are reported within 3 to 4 weeks from sample receipt, and the comprehensive test price is 2,800 AED, inclusive of pre‑test counselling and post‑ clinical discussion. This fee covers sample collection, sequencing, bioinformatics analysis, and final interpretation signed by a DHA‑licensed molecular geneticist. Direct insurance billing can be confirmed via WhatsApp.

ما هي مدة النتائج والتكلفة الإجمالية في الإمارات؟

تُصدر النتائج خلال 3 إلى 4 أسابيع من استلام العينة، والتكلفة الشاملة للفحص 2800 درهم إماراتي، تشمل الاستشارة الوراثية وجلسة مناقشة النتائج بعد التحليل.

Compliance & Data Protection

  • Licensed by DHA Facility No. 9834453; operates under MOHAP genetic testing regulations.
  • Strictly adheres to UAE Federal Decree‑Law No. 41 of 2024 (Art. 87), mandating genetic counselling and parental consent for minors.
  • UAE Cabinet Decision on Child Protection in Healthcare (2026) observed – all minor samples processed only after verified guardian authorization.
  • UAE Personal Data Protection Law (PDPL) compliant – genetic data encrypted at rest and in transit; no offshore storage.
  • ISO 9001:2015 Certified (Certificate No. INT/EGQ/2509DA/3139) for consistent quality and cold‑chain integrity.

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians